Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of CareNew Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical PotentialSEATTLE, WA / …